Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy

Area of Science:

• Pharmacology
• Virology
• Clinical Medicine

Background:

• Zidovudine is a key antiretroviral medication used in HIV treatment.
• Understanding the relationship between drug exposure and virological response is crucial for optimizing therapy.
• P24 antigenemia is a marker of HIV replication and disease progression.

Purpose of the Study:

• To analyze and model the pharmacokinetics of zidovudine.
• To model the decrease in P24 antigenemia.
• To investigate the correlation between zidovudine exposure and its efficacy in reducing P24 antigen levels.

Main Methods:

• Pharmacokinetic analysis using a compartmental model with 12 blood samples post-dose.
• Pharmacodynamic analysis of P24 antigenemia using an exponential decay model with samples collected every 3 days.
• Nonlinear regression to estimate pharmacokinetic and pharmacodynamic parameters for each patient.
• Correlation analysis between exposure and efficacy parameters.

Main Results:

• Significant correlation found between the coefficient of P24 reduction and the daily area under the curve (AUC) of zidovudine (P < 0.0014).
• The relationship was modeled using an Imax model, estimating the daily AUC for 50% antigenemia decrease at 2.32 mg x h/L.
• Average steady-state concentration for 70% maximal efficacy was estimated at 0.22 mg/L.

Conclusions:

• A significant relationship exists between zidovudine exposure and the reduction of P24 antigenemia.
• Large interpatient variability in zidovudine pharmacokinetics necessitates therapeutic drug monitoring.
• A clinical target concentration for zidovudine was defined to ensure optimal efficacy.